请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo Biosciences/Icotinib HCl/205847/2g
产品编号:205847-2g
市  场 价:¥73000.00
场      地:美国(厂家直采)
产品分类: 生化试剂>其他>其他试剂>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$3650.00
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo Biosciences/Icotinib HCl/205847/2g
商品介绍
Icotinib,alsoknownasBPI-2009,isanorallyavailablequinazoline-basedinhibitorofepidermalgrowthfactorreceptor(EGFR),withpotentialantineoplasticactivity.Icotinibselectivelyinhibitsthewild-typeandseveralmutatedformsofEGFRtyrosinekinase.ThismayleadtoaninhibitionofEGFR-mediatedsignaltransductionandmayinhibitcancercellproliferation.EGFR,areceptortyrosinekinase,isupregulatedinavarietyofcancercelltypes.

MedKooCat#:205847
Name:IcotinibHCl
CAS#:1204313-51-8(HCl)
ChemicalFormula:C22H22ClN3O4
ExactMass:
MolecularWeight:427.89
ElementalAnalysis:C,61.76;H,5.18;Cl,8.28;N,9.82;O,14.96


RelatedCAS#:1204313-51-8(HCl) 610798-31-7(freebase) 

Synonym:BPI2009;BPI2009;BPI-2009;Icotinib;Brandname:Conmana.

IUPAC/ChemicalName:N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-aminehydrochloride

InChiKey:PNNGXMJMUUJHAV-UHFFFAOYSA-N

InChiCode:InChI=1S/C22H21N3O4.ClH/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20;/h1,3-5,12-15H,6-11H2,(H,23,24,25);1H

SMILESCode:C#CC1=CC(NC2=C3C=C(OCCOCCOCCO4)C4=CC3=NC=N2)=CC=C1.[H]Cl


TechnicalData

Appearance:
Lightyellowsolidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

CertificateofAnalysis:
ViewcurrentbatchofCoA

QCData:
ViewNMR,ViewHPLC,ViewMS

SafetyDataSheet(MSDS):
ViewMaterialSafetyDataSheet(MSDS)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

IcotinibwasapprovedinChinain2011.


References

1:ChenX,ZhuQ,LiuY,LiuP,YinY,GuoR,LuK,GuY,LiuL,WangJ,WangZ,RøeOD,ShuY,ZhuL.Icotinibisanactivetreatmentofnon-small-celllungcancer:aretrospectivestudy.PLoSOne.2014May16;9(5):e95897.doi:10.1371/journal.pone.0095897.eCollection2014.PubMedPMID:24836053;PubMedCentralPMCID:PMC4023939.

2:PanH,LiuR,LiS,FangH,WangZ,HuangS,ZhouJ.EffectsofIcotinibonAdvancedNon-SmallCellLungCancerwithDifferentEGFRPhenotypes.CellBiochemBiophys.2014Apr29.[Epubaheadofprint]PubMedPMID:24777808.

3:GuanYS,HeQ,LiM.Icotinib:activityandclinicalapplicationinChinesepatientswithlungcancer.ExpertOpinPharmacother.2014Apr;15(5):717-28.doi:10.1517/14656566.2014.890183.Epub2014Mar4.PubMedPMID:24588695.

4:LiangW,WuX,FangW,ZhaoY,YangY,HuZ,XueC,ZhangJ,ZhangJ,MaY,ZhouT,YanY,HouX,QinT,DinglinX,TianY,HuangP,HuangY,ZhaoH,ZhangL.Networkmeta-analysisoferlotinib,gefitinib,afatinibandicotinibinpatientswithadvancednon-small-celllungcancerharboringEGFRmutations.PLoSOne.2014Feb12;9(2):e85245.doi:10.1371/journal.pone.0085245.eCollection2014.PubMedPMID:24533047;PubMedCentralPMCID:PMC3922700.

5:LiuD,JiangJ,ZhangL,TanF,WangY,ZhangD,HuP.ClinicalpharmacokineticsofIcotinib,ananti-cancerdrug:evaluationofdoseproportionality,foodeffect,andtolerABIlityinhealthysubjects.CancerChemotherPharmacol.2014Apr;73(4):721-7.doi:10.1007/s00280-014-2398-8.Epub2014Feb1.PubMedPMID:24488324.

6:ShaoL,ZhangB,HeC,LinB,SongZ,LouG,YuX,ZhangY.EfficacyandsafetyoficotinibinChinesepatientswithadvancednon-smallcelllungcancerafterfailureofchemotherapy.ChinMedJ(Engl).2014;127(2):266-71.PubMedPMID:24438614.

7:GuanY,ZhaoH,MengJ,YanX,JiaoS.Dramaticresponsetohigh-doseicotinibinalungadenocarcinomapatientaftererlotinibfailure.LungCancer.2014Feb;83(2):305-7.doi:10.1016/j.lungcan.2013.12.002.Epub2013Dec12.PubMedPMID:24370197.

8:ZhaoQ,WangY,TangY,PengL.Icotinibcombinedwithrapamycininarenaltransplantrecipientwithepidermalgrowthfactorreceptor-mutatednon-smallcelllungcancer:Acasereport.OncolLett.2014Jan;7(1):171-176.Epub2013Nov5.PubMedPMID:24348843;PubMedCentralPMCID:PMC3861587.

9:SunX,ZhengY.Retreatmentwithicotinibinapatientwithmetastaticlungadenocarcinoma.Tumori.2013May-Jun;99(3):e124-6.doi:10.1700/1334.14820.PubMedPMID:24158081.

10:ShiY,ZhangL,LiuX,ZhouC,ZhangL,ZhangS,WangD,LiQ,QinS,HuC,ZhangY,ChenJ,ChengY,FengJ,ZhangH,SongY,WuYL,XuN,ZhouJ,LuoR,BaiC,JinY,LiuW,WeiZ,TanF,WangY,DingL,DaiH,JiaoS,WangJ,LiangL,ZhangW,SunY.Icotinibversusgefitinibinpreviouslytreatedadvancednon-small-celllungcancer(ICOGEN):arandomised,double-blindphase3non-inferioritytrial.LancetOncol.2013Sep;14(10):953-61.doi:10.1016/S1470-2045(13)70355-3.Epub2013Aug13.PubMedPMID:23948351.

11:CamidgeDR.Icotinib:kick-startingtheChineseanticancerdrugindustry.LancetOncol.2013Sep;14(10):913-4.doi:10.1016/S1470-2045(13)70385-1.Epub2013Aug13.PubMedPMID:23948350.

12:YangX,ZhangH,QinN,LiX,NongJ,LvJ,WuY,ZhangQ,ZhangS.[Clinicalobservationoficotinibhydrochlorideinfirst-linetherapyforpulmonaryadenocarcinoma].ZhongguoFeiAiZaZhi.2013Jul;16(7):364-8.doi:10.3779/j.issn.1009-3419.2013.07.06.Chinese.PubMedPMID:23866667.

13:NongJ,QinN,WangJ,YangX,ZhangH,WuY,LvJ,ZhangQ,ZhangS.[Clinicaleffectsforpatientswithrecurrentadvancednon-smallcelllungcancertreatedwithicotinibhydrochloride].ZhongguoFeiAiZaZhi.2013May;16(5):240-5.doi:10.3779/j.issn.1009-3419.2013.05.05.Chinese.PubMedPMID:23676980.

14:LvC,MaY,FengQ,FangF,BaiH,ZhaoB,YanS,WuN,ZhengQ,LiS,ChenJ,WangJ,FengY,WangY,PeiY,FangJ,YangY.Apilotstudy:sequentialgemcitabine/cisplatinandicotinibasinductiontherapyforstageIIBtoIIIAnon-small-celllungadenocarcinoma.WorldJSurgOncol.2013Apr26;11:96.doi:10.1186/1477-7819-11-96.PubMedPMID:23621919;PubMedCentralPMCID:PMC3643858.

15:GaoZ,ChenW,ZhangX,CaiP,FangX,XuQ,SunY,GuY.Icotinib,apotentandspecificEGFRtyrosinekinaseinhibitor,inhibitsgrowthofsquamouscellcarcinomacelllineA431throughnegativelyregulatingAKTsignaling.BiomedPharmacother.2013Jun;67(5):351-6.doi:10.1016/j.biopha.2013.03.012.Epub2013Apr2.PubMedPMID:23602321.

16:MuX,ZhangY,QuX,HouK,KangJ,HuX,LiuY.UbiquitinligaseCbl-bisinvolvedinicotinib(BPI-2009H)-inducedapoptosisandG1phasearrestofEGFRmutation-positivenon-small-celllungcancer.BiomedResInt.2013;2013:726375.doi:10.1155/2013/726375.Epub2013Mar19.PubMedPMID:23586056;PubMedCentralPMCID:PMC3615596.

17:SongZ,YuX,CaiJ,ShaoL,LinB,HeC,ZhangB,ZhangY.[Efficacyoficotinibforadvancednon-smallcelllungcancerpatientswithEGFRstatusidentified].ZhongguoFeiAiZaZhi.2013Mar;16(3):138-43.doi:10.3779/j.issn.1009-3419.2013.03.04.Chinese.PubMedPMID:23514942.

18:GuA,ShiC,XiongL,ChuT,PeiJ,HanB.Efficacyandsafetyevaluationoficotinibinpatientswithadvancednon-smallcelllungcancer.ChinJCancerRes.2013Feb;25(1):90-4.doi:10.3978/j.issn.1000-9604.2012.12.07.PubMedPMID:23372346;PubMedCentralPMCID:PMC3555305.

19:ZhaoQ,WangYN,WangB.Sparedpre-irrADIatedareainpustularlesionsinducedbyicotinibshowingdecreasedexpressionsofCD1a+langerhanscellsandFGFR2.JpnJClinOncol.2013Feb;43(2):200-4.doi:10.1093/jjco/hys209.Epub2012Dec21.PubMedPMID:23264674.

20:ZhengY,FangW,XuN.Hand-footsyndromeinapatientwithmetastaticlungadenocarcinomainducedbyhigh-doseicotinib:Acasereportandreviewoftheliterature.OncolLett.2012Dec;4(6):1341-1343.Epub2012Sep10.PubMedPMID:23205134;PubMedCentralPMCID:PMC3506748.

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔